Dabigatran-d3

• Description:

  Dabigatran-d3 is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM) . Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) [1][2].

• Product Name Alternative:

  BIBR 953-d3; BIBR 953ZW-d3

• UNSPSC:

  12352005

• Hazard Statement:

  H225, H302+H312+H332, H319

• Target:

  Thrombin

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cardiovascular Disease

• Purity:

  99.53

• Solubility:

  DMSO : 10 mg/mL (ultrasonic; warming; adjust pH to 3 with 1 M HCL)

• Smiles:

  OC(CCN(C1=CC=CC=N1)C(C2=CC=C(C(N=C3CNC4=CC=C(C=C4)C(N)=N)=C2)N3C([2H])([2H])[2H])=O)=O

• Molecular Formula:

  C25H22D3N7O3

• Molecular Weight:

  474.53

• Precautions:

  H225, H302+H312+H332, H319

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98 (1) :155-62.|[3]Hauel NH, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002 Apr 25;45 (9) :1757-66.|[4]Wienen W, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007 Aug;98 (2) :333-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1246817-44-6]